Advertisement

Endocrine

, Volume 61, Issue 1, pp 169–172 | Cite as

Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma

  • Mélanie Claps
  • Sara Cerri
  • Salvatore Grisanti
  • Barbara Lazzari
  • Vittorio Ferrari
  • Elisa Roca
  • Paola Perotti
  • Massimo Terzolo
  • Sandra Sigala
  • Alfredo BerrutiEmail author
Research Letter

Introduction

Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumor that is actively secreting in approximately 50% of adult patients. Cushing’s syndrome is the most commonly associated endocrine disorder [1] that negatively influences the outcome of ACC patients, due to cortisol-related comorbidities [2] and the immunosuppressive effects of cortisol excess that may promote tumor progression [3]. The management of ACC patients is challenging and demanding because physicians have to deal with either oncological or endocrinological issues [4].

Currently, the standard systemic treatment for advanced ACC patients not amenable to surgery with radical intent is mitotane, administered either alone or in combination with etoposide, doxorubicin and cisplatin (EDP-M scheme) [1]. Mitotane exerts both adrenolytic and cytotoxic activities [5] and has a narrow therapeutic index defined by circulating levels of the drug between 14 and 20 mg/L [6]. These concentrations have been...

Notes

Acknowledgements

Grant IG 2015-17678 from Associazione Italiana per la Ricerca sul Cancro (AIRC) to MT. Private grant from the amateur dramatics group “Attori non per caso”, parish church of Collio Valtrompia (Brescia) to BL.

Funding

This study was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC), grant n. IG 2015-17678 to MT and by a private grant from the amateur dramatics group “Attori non per caso”, parish church of Collio Valtrompia (Brescia) to BL.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    M. Terzolo, F. Daffara, A. Ardito, B. Zaggia, V. Basule, L. Ferrari, A. Berruti, Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37, 207–217 (2014).  https://doi.org/10.1007/s40618-013-0049-2 CrossRefPubMedGoogle Scholar
  2. 2.
    A. Berruti, M. Fassnacht, H. Haak et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur. Urol. 65, 832–838 (2014).  https://doi.org/10.1016/j.eururo.2013.11.006 CrossRefPubMedGoogle Scholar
  3. 3.
    P. Malandrino, A. Al Ghuzlan, M. Castaing, J. Young, B. Caillou, J.P. Travagli, D. Elias, T. de Baere, C. Dromain, A. Paci, P. Chanson, M. Schlumberger, S. Leboulleux, E. Baudin, Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr. Relat. Cancer. 17, 797–807 (2010).  https://doi.org/10.1677/ERC-09-0341 CrossRefPubMedGoogle Scholar
  4. 4.
    A. Berruti, E. Baudin, H. Gelderblom, H.R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis; ESMO Guidelines Working Group., Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii131–vii138 (2012).  https://doi.org/10.1093/annonc/mds231 CrossRefPubMedGoogle Scholar
  5. 5.
    S. Hahner, M. Fassnacht, Mitotane for adrenocortical carcinoma treatment. Curr. Opin. Investig. Drugs. 6(4), 386–394 (2005)PubMedGoogle Scholar
  6. 6.
    I.G. Hermsen, M. Fassnacht, M. Terzolo et al. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin 96, 1844–1851 (2011).  https://doi.org/10.1210/jc2010-2676 CrossRefGoogle Scholar
  7. 7.
    M. Terzolo, A. Pia, A. Berruti, A. Osella Gm Alì, V. Carbone, E. Testa, L. Dogliotti, A. Angeli, Lowe-dose monitored mitotane treatment achieve the therapeutic range with manageable side effects in patients with adrenocortical cancer. J. Clin. Endocrinol. Metab. (2000).  https://doi.org/10.1210/jcem.85.6.6619
  8. 8.
    E. Daniel, S. Aylwin, O. Mustafa et al. Effectiveness of metyrapone in treating cushing’s syndrome: a retrospective multicenter study in 195 patients. J. Clin. Endocrinol. Metab. 100, 4146–4154 (2015).  https://doi.org/10.1210/jc.2015-2616 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    J.A. Verhelst, P.J. Trainer, T.A. Howlett, L. Perry, L.H. Rees, A.B. Grossman, J.A. Wass, G.M. Besser, Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin. Endocrinol. 35(2), 169–178 (1991)CrossRefGoogle Scholar
  10. 10.
    M. Kroiss, M. Quinkler, W.K. Lutz, B. Allolio, M. Fassnacht, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol. 75, 585–591 (2011).  https://doi.org/10.1111/j.13652265.2011.04214.x CrossRefGoogle Scholar
  11. 11.
    Metyrapone. In: DRUGDEX® System [Internet database]. (Thomson Micromedex, Greenwood Village, Colo). Updated periodically, http://www.micromedexsolutions.com. Accessed 18 Jan 2016
  12. 12.
    I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619–4629 (2009).  https://doi.org/10.1200/JCO.2008.17.2775 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    S.P. Rajeev, S. McDougall, M. Terlizzo, D. Palmer, C. Daousi, D.J. Cuthbertson, Evolution in functionality of a metastatic pancreatic neuroendocrine tumor (pNET) causing Cushing’s syndrome: treatment response with chemotherapy. BMC Endocr. Disord. 14, 70 (2014).  https://doi.org/10.1186/1472-6823-14-70 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    M. Wojcik, A. Kalicka-Kasperczyk, T. Luszawska-Kutrzeba, W. Balwierz, J.B. Starzyk, The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Case Report. Neuro Endocrinol. Lett. 36(7), 653–655 (2015)PubMedGoogle Scholar
  15. 15.
    R.E. Galinsky, E.B. Nelson, D.E. Rollins, Pharmacokinetic consequences and toxicologic implications of metyrapone-induced alterations of acetaminophen elimination in man. Eur. J. Clin. Pharmacol. 33(4), 391–396 (1987)CrossRefPubMedGoogle Scholar
  16. 16.
    A. Berruti, M. Terzolo, P. Sperone et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12(3), 657–666 (2005).  https://doi.org/10.1677/ec.1.01025 CrossRefPubMedGoogle Scholar
  17. 17.
    M. Fasssancht, M. Terzolo, B. Allolio et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012).  https://doi.org/10.1056/NEJMoal1200966 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Mélanie Claps
    • 1
  • Sara Cerri
    • 1
  • Salvatore Grisanti
    • 1
  • Barbara Lazzari
    • 1
  • Vittorio Ferrari
    • 1
  • Elisa Roca
    • 1
  • Paola Perotti
    • 2
  • Massimo Terzolo
    • 2
  • Sandra Sigala
    • 3
  • Alfredo Berruti
    • 1
    Email author
  1. 1.Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthASST Spedali Civili di Brescia, University of BresciaBresciaItaly
  2. 2.Internal Medicine 1, Department of Clinical and Biological Sciences, S. Luigi HospitalUniversity of TurinTorinoItaly
  3. 3.Section of Pharmacology, Department of Molecular and Translational MedicineUniversity of BresciaBresciaItaly

Personalised recommendations